AP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer. It is being pursued by Access Pharmaceuticals, Inc.
- Mechanism
- Curator reviewed
Utilizing the biocompatible water-soluble polymer HPMA as a drug carrier, AP5346 links DACH platinum to the polymer in a manner which permits the selective release of platinum in tumors. The polymer capitalizes on the biological differences in the permeability of blood vessels at tumor sites versus normal tissue. In this way, tumor selective delivery and platinum release is achieved. Once delivered to the tumor, platinum binds preferentially to the guanine and cytosine moieties of DNA, leading to cross-linking of DNA, thus inhibiting DNA synthesis and function.
- Primary indication
- For the treatment of various forms of cancer.Curator reviewed
- Code names
- AP5346
What you can answer from here — as of June 12, 2020
Which companies are running trials of AP5346, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account